Warhound's $200m seed: who backed it, and what the release leaves out

Warhound plans to rebuild a domestic supply of working dogs for the US military, law enforcement and emergency responders by combining genetics, cloning, training and equipment from Anduril, according to the press release it issued on emerging from stealth in October 2026. The release says the idea came from Ben Lamm, who co-founded Colossal Biosciences, and Palmer Luckey, and that investors backed it with a $200 million seed round. Luckey founded the defense company Anduril Industries.

The release says the Department of War's Military Working Dog Program includes more than 2,200 working dog teams used for detection and patrol work. More than 80% of US military working dogs are acquired from Europe, the company says, and after a pipeline of roughly three years less than half of the dogs procured are deemed fit for service. These are Warhound's figures; Polstob has not checked them independently.

Warhound is based in Texas and led by chief executive David Spirk, who the release says was previously the first chief data officer for the Department of War and the first for US Special Operations Command. It says the American Humane Society will guide the company, certify its training programmes and help reunite retired dogs with their former handlers.

The release names 12 backers, 'among others': In-Q-Tel, Sequoia Capital, ARK Invest, Franklin Templeton, 8VC, USIT, Bob Nelsen, Breyer Capital, CAZ Investments, Neogenesis, Builders VC and Lux Capital. The release does not say who led the $200 million round or how much any investor put in.

In-Q-Tel, also known as IQT, says it was "set up in 1999 by the CIA as an independent, not-for-profit strategic investment firm", and that it is neither a government entity nor part of the CIA. Its government partners include the CIA, the FBI and the National Security Agency. IQT says its technology development agreements typically involve $500,000 to $3 million, and its equity-only investments $250,000 to $500,000, in return for a small equity stake and board observer status. It often invests alongside venture capital firms, it says.

The release says Warhound combines Colossal's genetics platform, biobanking of top-performing dogs and cloning with training and animal care, and describes the company as using biotechnology licensed from Colossal Biosciences. Colossal says on its website that its dire wolf pups were produced through 20 edits in 14 gray wolf genes, and that for the cloning it isolated cells from blood instead of taking tissue biopsies. It says four red wolves were also cloned alongside the dire wolf work.

Through a partnership, every Warhound dog will be equipped with Anduril's cybernetic augments, software and battlefield situational awareness, the release says, and dog-and-handler teams will connect to Anduril capabilities including eye and ear protection. Anduril says it identifies problems, privately funds its research and development and sells finished products off the shelf, instead of waiting for customers to say what they need.